RecruitingNot Applicable

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

United States8 participantsStarted 2026-02-09

Plain-language summary

The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female subjects ≥ 18 years of age with allogeneic HSCT Exclusion Criteria: * Receiving an investigational GVHD treatment within 28 days of study entry; (2) active acute GVHD; and (3) taking any medication known to be CYP3A4 inducers. * Pregnancy is an exclusion criterion for stem cell transplant. Pregnant women are not included in this study. Non-viable neonates will not be included in this study. Patients with cognitive impairments will not be included in this study. Patients aged less than 18 years old will not be included.

What they're measuring

Safety and adverse events (AEs

Timeframe: Through study completion; an average of 1 year

Trial details

NCT IDNCT07127926

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

Contact for this trial

Amin Alousi, MD

(713) 745-8613 aalousi@mdanderson.org

View on ClinicalTrials.gov More Chronic Graft Versus Host Disease trials